The growth of multinational pharmaceutical companies such as Johnson and Johnson is weak, betting on innovative drugs

Looking at the first half of 2017, most drug companies posted flat growth of single digits, while Pfizer, Gilead and AstraZeneone fell by more than double digits.
, on the other hand, some of the growth was driven by new drugs, such as Roche's Tecentriq, the new drug Ocrevus for multiple sclerosis, Novartis' single-drug Cosentyx, and its new breast cancer drug, Kisqali. The listing and promotion of some drugs in emerging markets has also been boosted by the approval of Pfizer's pneumonia vaccine, Prevnar, in China, which contributed 4 per cent growth in the first half of the year, and Gardasil, merchington's cervical cancer vaccine, which grew nearly 30 per cent in the first half, mainly driven by the Asia-Pacific and Brazilian markets.
World Preview 2017, Outlook to 2022, released in June, predicts that global prescription drug sales will grow to $1.06 trillion by 2022 at a strong 6.5 percent compound annual growth rate. In 2022, AbbVie's Shumeile will hold the "Drug King" seat with $15.901 billion in sales, and orphan drug sales will grow 32 percent, while the risks posed by its $194 billion sales with the advent of biosimilars may mark the dawn of a second patent cliff. 1, weak growth
Johnson and Johnson on July 18, announced the first half of 2017 results, with total revenue of $36.605 billion, ranking first in the world, up 1.8% year-on-year. Prescription drugs, consumer health care and medical devices contributed $168.80, 67.06 and $13.019 billion, respectively, from the three major business segments.
first half of last year, Johnson and Johnson completed a $30 billion deal for rare disease drug company Acotalon Actelion. Founded in Switzerland in December 1997 and IPOd on the Swiss Stock Exchange in 2000, Acoteron has a number of mature products with rare disease drugs, particularly in the field of pulmonary hypertension.
the deal was completed, Johnson and Johnson obtained Actelion's Tracleer, Opsumit and Uptravi portfolios of drugs to treat pulmonary hypertension. According to Actelion's 2016 results, the three drugs had annual sales of 1.02 billion, 831 million and 245 million Swiss francs, respectively, for a total of 2.412 billion Swiss francs. As a result, Johnson and Johnson increased its full-year revenue forecast to $75.8 billion to $76.1 billion.
, Pfizer, Novaral and Sanofi, who finished second to fifth, entered the $20 billion "club" in the first half of the year.
Roche's July 27 results showed that roche achieved a net profit of 5.57 billion Swiss francs (4.92 billion euros) in the first half of this year, up 2% YoY;
Schwan, president of the Roche Group, said the pharmaceutical and diagnostic divisions had both achieved good results through the launch of new products. In particular, Ocrevus, which successfully marketed two forms of multiple sclerosis, was welcomed. Based on first-half results, Roche revised and improved its full-year sales growth rate.
first-half revenue was $25.675 billion, down 2 percent from a year earlier. Pfizer's product line is rich, but the better performing products are the anticoagulant Eliquis (51%), the breast cancer drug Ibrace (63%), and the rheumatoid arthritis drug Xeljanz (42%).
For Pfizer's first-half results, Pfizer CEO Ian Read said he was in line with expectations and optimistic about the pipeline: "There will be 25-30 new drugs on the market over the next five years, 15 of which have the potential to become a bombshell, and half of the 15 new drugs will be approved by 2020." Pfizer's strategy for the future remains to maximize market opportunities while fully advancing pipeline product development and controlling company costs. Novar
revenue rose 1 per cent to $23.8bn in the first half. Among them, the generics business unit Sandoz net income of $4.9 billion (-2%), ophthalmology business Alcon net income of $1.9 billion (-2%). Novart excelled in emerging markets, with the Chinese market growing by 10 per cent.
's most popular recent CAR-T therapy CTL-019 was unanimously recommended by the FDA's Oncology Expert Advisory Committee 10:0 for the treatment of recurring or incurable children, adolescent B-cell acute lymphoblastic leukemia, and the opening of two other giants, Kite Pharma and JUNO, went public with little suspense.
other big increases were AbbVie, which reported revenue of $13.482 billion in the first half, up 8.6 percent year-on-year, mainly from star products Suche Humira and Erudini Imbruvica, which contributed $88.34 billion (14.3 percent) and $1.177 billion (43.6 percent), respectively, in the first half.
since it took over in 2012, to 2016, Symele has been the world's top-selling biologics for five consecutive years and has continued to grow at a high rate, with global sales of $16,078 million in 2016. Evaluate Pharma predicts that Shumeile will remain the "king of medicine" by 2022. The most eye-catching increase on the
list came from Blinger Ingeham (BI), which posted first-half sales of 9.2 billion euros, an exchange rate-adjusted growth rate of 24 per cent, and Simone Menne, executive board member for finance, said: "The growth was mainly due to the integration of Merial's animal health business, which more than tripled its net sales in the animal health sector. "
also in terms of medical devices, gps (GE, Philips, Siemens) remains strong, with revenues ranking GE ($8.99 billion), Philips (8.165 billion euros) and Siemens (6.723 billion euros), respectively, up 2 to 3 percent.
's earnings were not as good as those of the three, but its second-quarter sales in the medical device sector were strong, with global sales of $2.6 billion, up 3.2 per cent year-on-year. Among them, sales of products related to the diabetes care business increased by 25% year-on-year. The merger of Abbott and St. Jude Healthcare has made it the world's No. 1 in neurodevestrage. Driven by key markets such as China, Brazil, Russia and India, Abbott's drug business reported global sales of $1bn in the second quarter, up 3.5 per cent year-on-year, and diagnostics sales of $1.3bn, up 5.4 per cent year-on-year. 2, innovative drugs are the mainstreamfor the major multinational pharmaceutical companies, "new drug research and development, sales strategy, as well as mergers and acquisitions, to enrich the product line have an impact on the list changes." In contrast, because the new drug market has a certain time span, in a short period of time mergers and acquisitions to improve sales has a more direct role. Yuan Jijun, director of genetic research and development at Jikai, told the 21st Century Economic Report, "In addition, the market for anti-tumor and immunologic drugs is growing, and there are more and more opportunities for market segments." "
, Novarma, Pfizer and Roche will be between the top three global prescription drug sales by 2022, according to Evaluate Pharma. Among them, innovative drugs and tumors remain the largest therapeutic areas with the largest sales in 2016-2022 (12.7% compound annual growth rate);
TOP15 oncology drug could generate nearly $90 billion in sales by 2022, while Celgene's Revlimid, which targets adaptations such as multiple myeloma and set cell lymphoma, will become the world's highest-sales oncology drug by 2022, at $14.19 billion.
the research and development layout of major pharmaceutical companies, in the anti-tumor drugs and immunologic drugs have their own focus, fierce competition. High-focused drugs include BMS Opdivo for allergies such as melanoma and non-small cell lung cancer (NSCLC), Mercedon's product Keytruda; Johnson and Johnson Imbruvica Irutini; and Roche's Tecentriq, the FDA's first approved immunotherapy drug for bladder cancer.
In the first half of this year, in the prescription drug business, Johnson and Johnson's stronger growth of drugs included Utek monoanti (17.3%), Lipiverin (26.6%), tumor line, BTK inhibitor erutinib and daratumumab for multiple myeloma, up 54.5% and 165.1%, respectively.
has long been considered a leader in oncology, but EP sees Celgene and Novaral as strong challengers in the field. Celgene (15 per cent) and Shire (10 per cent) are expected to see the fastest growth in sales by 2020.
research and development, Biogen's aducanumab and Johnson and Johnson's abalutamide are expected to be the most valuable research and development projects; global pharmaceutical research and development spending is expected to grow 2.4 percent to $181 billion in 2022, and Roche will be the largest investor in pharmaceutical research and development in 2022.
segment, No. and Nordisk will still have a higher share of the antidiabetic market by 2022; AbbVie will dominate the anti-rheumatoid market; GSK will lead Merck and Pfizer in the vaccine market, but Pfizer's pneumococcal vaccine Prevnar13 remains the best-selling vaccine product; and Gilead will remain a leader in the antiviral market because of its HIV portfolio.
in the field of tumors, Opdivo will compete with Revlimid for the world's best-selling product, but Keytruda will eliminate Opdivo as a best-selling PD-1/PD-L1 product in 2022, with EP giving sales forecasts for 2022 of Opdivo ($9.9 billion) and Keytruda ($9.5 billion). (21st Century Economic Report)